Vivos Therapeutics (NASDAQ:VVOS) Issues Earnings Results, Misses Estimates By $0.16 EPS

Vivos Therapeutics (NASDAQ:VVOS) released its quarterly earnings data on Wednesday. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.16), Zacks reports. Vivos Therapeutics had a negative net margin of 121.37% and a negative return on equity of 849.22%. The business had revenue of $5.14 million during the quarter, compared to analyst estimates of $4.35 million.

Vivos Therapeutics Stock Performance

NASDAQ:VVOS opened at $0.59 on Thursday. The firm has a market capitalization of $8.09 million, a PE ratio of -0.29 and a beta of 6.25. The business’s fifty day moving average price is $1.04 and its 200 day moving average price is $1.64. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.24 and a quick ratio of 0.24. Vivos Therapeutics has a 12 month low of $0.57 and a 12 month high of $7.95.

Insider Buying and Selling

In other Vivos Therapeutics news, major shareholder Michael C. Skaff bought 1,353,625 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were purchased at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the acquisition, the insider directly owned 1,353,625 shares of the company’s stock, valued at $1,813,857.50. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vivos Therapeutics

Several large investors have recently bought and sold shares of VVOS. XTX Topco Ltd acquired a new position in Vivos Therapeutics in the second quarter valued at $65,000. B. Riley Wealth Advisors Inc. acquired a new position in Vivos Therapeutics in the second quarter valued at $220,000. DRW Securities LLC boosted its stake in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after acquiring an additional 74,441 shares in the last quarter. Finally, Connective Capital Management LLC acquired a new position in Vivos Therapeutics in the third quarter valued at $620,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on VVOS. HC Wainwright decreased their price objective on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a report on Friday, April 17th. Ascendiant Capital Markets decreased their price objective on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.75.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.